FDA批准对结肠癌进行新的组合治疗,试验反应率为61%。 FDA approves new combo treatment for colorectal cancer, showing 61% response rate in trials.

林业发展局已核准对有BRAF V600E突变的转移性直肠癌病人进行新治疗,结合了encorafenib、cetuximab和mFOLFOX6化疗。 The FDA has approved a new treatment for metastatic colorectal cancer patients with a BRAF V600E mutation, combining encorafenib, cetuximab, and mFOLFOX6 chemotherapy. 这一决定是在第3阶段试验结果显示总体答复率为61%之后作出的,而仅化疗一项答复率为40%。 This decision follows phase 3 trial results showing a 61% overall response rate, compared to 40% for chemotherapy alone. 这种治疗为选择机会有限的病人带来了希望,建议每天用300毫克的encorafenib剂量进行治疗。 The treatment offers hope for patients with limited options and is recommended at a 300 mg dose of encorafenib daily.